K
Kleo
Targeted immunotherapy company developing synthetic bispecific therapies to enhance antibody function
About Kleo
Kleo Pharmaceuticals is a biotechnology company focused on developing targeted immunotherapies. The company specializes in creating synthetic bispecific therapies designed to emulate or enhance the function of natural antibodies. These therapies are aimed at treating various diseases, including multiple myeloma and COVID-19. Kleo Pharmaceuticals operates primarily in the biopharmaceutical market, serving healthcare providers and patients who require advanced therapeutic options. The company's business model revolves around research and development, clinical trials, and eventual commercialization of its proprietary therapies. Revenue is generated through partnerships, grants, and future sales of approved treatments.
Source: Dealroom company dataAt a glance
- Founded
- 2015
- Headquarters
- New Haven, United States
- Sector
- Health
Knowledge graph
More headlines
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A2 investors entered at this stage
Biohaven
PeptiDream
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Kleo on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Kleo on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.